SCHEMBL20147652

SCHEMBL20147652

Cc1ncccc1C(=O)NC1(C)CCN(C(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.48
RET P07949 1/20 0.41
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
PARP1 P09874 2/20 0.39
HRH3 Q9Y5N1 1/20 0.38
POLB P06746 1/20 0.37
KIF18A Q8NI77 3/20 0.36
HCN4 Q9Y3Q4 2/20 0.36
HCN1 O60741 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
STING1 Q86WV6 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068973 0.86 P2RX7 (0.51) P2RX7RETDRD2DRD3POLB
SCHEMBL20147649 0.83 RET (0.41) P2RX7RET
SCHEMBL20147989 0.83 P2RX7 (0.48) P2RX7RETDRD2DRD3POLB
SCHEMBL25504250 0.83 P2RX7 (0.51) P2RX7RETDRD2DRD3POLB
SCHEMBL20068953 0.82 P2RX7 (0.47) P2RX7HCN4HCN1KMT2AL3MBTL1
SCHEMBL20147641 0.82 P2RX7 (0.38) P2RX7RETPARP1HRH3TRPV4
SCHEMBL20147673 0.81 RET (0.38) P2RX7RETPARP1
SCHEMBL20147632 0.81 RET (0.41) P2RX7RETPARP1
SCHEMBL20147607 0.80 KDM4E (0.47) RETKMT2AL3MBTL1
SCHEMBL20147610 0.80 RET (0.51) RETTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 P2RX7 1456/4885RET 1/4885DRD2 3425/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 P2RX7 1456/4885RET 1/4885DRD2 3425/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 P2RX7 1456/4885RET 1/4885DRD2 3425/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 P2RX7 1456/4885RET 1/4885DRD2 3425/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 P2RX7 1456/4885RET 1/4885DRD2 3425/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 P2RX7 1456/4885RET 1/4885DRD2 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.